<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2-560-12
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2012
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        MEDICAINE 2% CARTRIDGE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        MEPIVACAINE HYDROCHLORIDE,ADRENALINE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        20,0.01819
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Dental use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution for injection in cartridge
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        2
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        50
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Cartridge
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        94.60
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="LES LABORATOIRES MEDIS" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            LES LABORATOIRES MEDIS
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 530]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Salehiya Trading Co.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            LES LABORATOIRES MEDIS
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        N01BB53
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>MEDICAINE 2% is given by inject ion to cause loss of feeling before and during dental procedures. It contains two active ingredients:<br />&bull; mepivacaine hydrochloride, a local anaesthetic which prevents pain ,<br />&bull; adrenaline, a vasoconstrictor which makes the effect last longer. Adrenaline narrows the blood vessels at the site of injection, which keeps the anaesthetic where needed for a longer time. It also controls the bleeding during the surgery.<br />MEDICAINE 2% is for children over 4 years old and adults.</p><p>Only a dentist can administer this product.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not use MEDICAINE 2%</strong></p><p>&bull; if you are allergic (hypersensitive) to the active ingredient (mepivacaine hydrochloride) or to any of the other ingredients (refer to section 6).<br />&bull; you are allergic to local anaesthetics called amide type anaesthetics,<br />&bull; if you have a high blood pressure (arterial hypertension),<br />&bull; if you have particular heart or blood vessels disease (coronary or valvular cardiac disease),<br />&bull; if you are taking or have taken medicines for depression in the last two weeks,<br />&bull; in children under 4 years old.</p><p><strong>Take special care with MEDICAINE 2%</strong><br />before receiving this medicine, tell your dentist if:</p><p>&bull; you have problems with your heart,<br />&bull; you have problems with your liver,<br />&bull; you have problems with your kidneys,<br />&bull; you have a severe infection or an inflammation in the area where the injection will be done.<br />&bull; you are epileptic,<br />&bull; you have troubled breathing.</p><p><strong>Using other medicines</strong><br />Please tell your dentist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription.<br />&bull; Do not use MEDICAINE 2% if you are taking or have taken medicines for depression in the last two weeks.<br />Your dentist should take special attention if you are taking the following medicines:<br />&bull; medicines used to reduce your blood pressure (e.g. betablockers like propranolol or vasopressor drugs like dihydroergotamine),<br />&bull; medicines used to reduce patient apprehension (e.g. sedatives). In that case, the dosage of anaesthetic should be reduced.<br />&bull; medicines used to treat some psychiatric disorders called phenothoazines.<br />&bull; medicines used for anaesthesia (e.g. chloroform, halothane, cyclopropane, trichloroethylene).</p><p><strong>Pregnancy and breast‐feeding</strong><br />This medicine should be used with caution during pregnancy or breast‐feeding.<br />Ask your dentist for advice before taking any medicine.</p><p><strong>Driving and using machines</strong><br />If you experience side effects, including dizziness or blurred vision, you should not drive or operate machinery until these effects have disappeared.</p><p><strong>Important information about some ingredients of MEDICAINE 2%</strong><br />MEDICAINE 2% contains less than 1 mmol (23mg) sodium per cartridge, i.e. essentially &quot;sodium free&quot;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Your dentist will ex to you why you are being treated with MEDICAINE 2%. He will choose the formula and adjust the dosage according to your age, your health and the dental procedure. One cartridge is usually sufficient but your dentist may give you a greater quantity.<br />MEDICAINE 2% is injected between two teeth. It should not be injected into a blood vessel.</p><p><strong>If your dentist uses more MEDICAINE 2%than he should</strong><br />If you think you may have been given too much of this injection and feel unwell (see section 4, possible side effects), tell your dentist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, MEDICAINE 2%, can cause side effects, although not everybody gets them. While you are in your dentist office, your dentist will carefully follow the effects of MEDICAINE 2%.</p><p><br />Administration of MEDICAINE 2% may cause high plasma levels in active substances<br />(mepivacaine and/or adrenaline), especially overdose or unintended injection. Symptoms include: effects on your senses (hearing, sight, behaviour), effects on your heart or blood vessels, effects on your immune defences (diminished tolerance). As complications to the manifestations of progressive cerebral hypoxia (decrease below normal levels of oxygen in tissue) and seizure or cardiovascular problem, sweating, feeling of faintness, changes in pulse or sensorium, vasovagal reaction might occur. The stimulation of the senses due to adrenaline appears by increasing fear and anxiety, tension, restlessness, throbbing, headache, tremor, weakness, pallor, respiratory difficulty.<br />&nbsp;</p><p><strong>The following common side effects affect between 1 and 10 of every 100 patients treated:</strong><br />Failure of cardiac circulation (cardiovascular collapse) which may lead to cardiac arrest, loss or abnormality of rhythm (arrhythmia or dysrhythmia), conduction disorders, drop in blood pressure (hypotension), convulsions, feeling of wellbeing commonly exaggerated (euphoria), unconsciousness, malaise, confusion, dizziness, headache; if you are in an upright position, a vasovagal reaction (relating<br />to the action of the nerve upon the blood vessels) may develop, slow or rapid heartbeats (bradycardia or tachycardia), irregular pulsation of heart (palpitations), lightheadedness, feeling nervous (nervousness), apprehension, agitation, drowsiness, buzzing in the ears (tinnitus), blurred or double vision, nausea, vomiting, sensations of heat, cold or numbness, uncontrolled eye movement (twitching), trembling.<br />&nbsp;</p><p><strong>The following rare side effects affect between 1 and 1000 of every 10,000 patients treated:</strong><br />&bull; Abnormality of rhythm of ventricle (ventricular fibrillation)<br />&nbsp;</p><p><strong>The following very rare side effects affect 1 of 10,000 patients treated:</strong><br />&bull; Severe allergic reactions (anaphylactoid reactions) characterized by swelling of the face, lips and/or tongue, difficulty breathing.<br />&bull; Allergic reactions characterized by skin rash (cutaneous lesions), eruption of itching wheals (urticaria), swelling (edema).<br />If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your dentist, doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep out of the reach and sight of children.<br />It is most unlikely that you will be asked to look after this medicine.<br />Your dentist will not use this medicine after the expiry date which is stated on the package. The expiry date refers to the last day of that month.<br />Your dentist will keep it up to 25&deg;C, stored in the original container (protected from light). It should not be frozen.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <ul><li>Active substance: each ml of solution for injection contains:</li></ul><p>- 20 mg of mepivacaine hydrochloride (for 1 ml),<br />- 0.01819 mg of adrenaline (epinephrine) (for 1 ml).</p><ul><li>&nbsp;The other ingredients are: sodium chloride, sodium metabisulfite and water for injection.</li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                It is a clear and colourless solution for injection.
MEDICAINE 2% is available in boxes containing 50 cartridges of 1.8 ml.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>For any information about this medicinal product, please contact the local representative of the Marketing Authorisation Holder:<br />Salehiya Trading Establishment<br />(Medical equipment &amp; pharmaceuticals)<br />P.O.Box: 991, Riyadh 11421- Kingdom of Saudi Arabia<br />Tel: 00 966 1 46 46 955<br />Fax: 00 966 1 46 34 362</p><p>To report any side effect(s):<br />&bull; Saudi Arabia:<br />&bull; The National Pharmacovigilance and Drug Safety Centre (NPC)<br />&bull;&nbsp; Fax: +966-11-205-7662<br />&bull;&nbsp; Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.<br />&bull;&nbsp; Toll free phone: 8002490000<br />&bull;&nbsp; E-mail: npc.drug@sfda.gov.sa<br />&bull;&nbsp; Website: www.sfda.gov.sa/npc</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in: 09/2018
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>يتم إعطاء ميديكاين عن طريق الحقن لإحداث فقدان الإحساس قبل وأثناء إجراءات بالأسنان.<br />أنه يحتوي على مكونان نشطان:<br />&bull;ميبيفاكايين هيدروكلوريد ، مخدر موضعي يمنع الألم ،<br />&bull;الأدرينالين ، مضيق للأوعية مما يجعل التأثير يدوم لفترة أطول .الأدرينالين يضيق الأوعية الدموية في موقع الحقن، والذي تحافظ<br />على التخدير عند الحاجة لفترة أطول .كما يسيطر على النزيف أثناء الجراحة..<br />ميديكاين 2% يمكن إستعماله للأطفال الذين تزيد أعمارهم عن 4 سنوات والبالغين.<br />يمكن فقط لطبيب الأسنان إستعمال هذا المنتج.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>لا تستخدم ميديكاين</strong><br />&bull; إذا كان لديك حساسية (فرط حساسية) للمكون النشط (ميبيفاكايين هيدروكلوريد) أو لأي من المكونات الأخرى (راجع القسم 6)<br />&bull; إذا كنت تعاني من حساسية تجاه أدوية التخدير الموضعي من صنف أمنواميد ،<br />&bull; إذا كنت تعاني من ارتفاع ضغط الدم (ارتفاع ضغط الدم الشرياني )،<br />&bull; إذا كنت تعاني من مرض معين في القلب أو في الشرايين (مرض القلب التاجي أو صمامات القلب)،<br />&bull; إذا كنت تتناول أو تأخذ أدوية للاكتئاب في آخر أسبوعين ،<br />&bull; عند الأطفال دون سن 4 سنوات من العمر.</p><p><strong>المحاذير والإحتياطات</strong><br />&bull; قبل تلقي هذا الدواء ، أخبر طبيب الأسنان إذا:<br />&bull; لديك مشاكل مع قلبك<br />&bull; لديك مشاكل مع كبدك ،<br />&bull; لديك مشاكل مع كليتيك ،<br />&bull; لديك نوبات صرع،<br />&bull;لديك اضطراب في التنفس.<br />&bull; لديك عدوى شديدة أو التهاب في المنطقة حيث سيتم إجراء الحقن.</p><p><strong>الأدوية الأخرى و ميديكاين %2</strong></p><p>يرجى إخبار طبيب الأسنان إذا كنت تتناول أو أخذت مؤخرًا أي أدوية أخرى، بما في ذلك الأدوية التي تم الحصول عليها دون<br />وصفة طبية.<br />يجب أن يهتم طبيب الأسنان الخاص بك إذا كنت تتناول الأدوية التالية:<br />&bull;الأدوية المستخدمة لخفض ضغط الدم (مثل مضادات الذهان مثل عقار بروبرانولول أو أدوية الأوعية الدموية مثل ديهدروتغوتامين )،<br />&bull;الأدوية المستخدمة للحد من مخاوف المريض (مثل المهدئات ). في هذه الحالة ، يجب تقليل جرعة المخدر.<br />&bull;الأدوية المستخدمة لعلاج بعض الاضطرابات النفسية المعروفة باسم فنثيزين.<br />&bull;الأدوية المستخدمة للتخدير (مثل كلوروفورم ، هالوثان ، سايكلوبروبان ، ثلاثي كلور إيثيلين)</p><p><strong>الحمل والرضاعة الطبيعية والخصوبة</strong></p><p>ينبغي استخدام هذا الدواء بحذر أثناء فترة الحمل أو الرضاعة الطبيعية.<br />اسأل طبيب الأسنان للحصول على المشورة قبل تناول أي دواء.</p><p><strong>القيادة واستخدام الآلات</strong><br />إذا كنت تعاني من آثار جانبية، بما في ذلك الدوخة أو عدم وضوح الرؤية، يجب عليك عدم قيادة السيارة أو تشغيل الآلات حتى تختفي هذه التأثيرات.</p><p><strong>معلومات مهمة حول بعض مكونات ميديكاين</strong></p><p>يحتوي MEDICAINE 2% على أقل من 1 ملمول ( 23 ملغ) من الصوديوم لكل خرطوشة ، أي يمكن إعتباره أساسًا &quot;خالٍ من الصوديوم&quot;.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>سوف يشرح لك طبيب الأسنان سبب علاجك بميديكاين 2% . سيختار الصيغة ويضبط الجرعة وفقاً لعمرك وصحتك ونوعية<br />التدخل الطبي المطلوب. عادة ما تكون خرطوشة واحدة كافية ولكن طبيب الأسنان الخاص بك قد يعطيك كمية أكبر.<br />يتم حقن ميديكاين 2% بين الأسنان. لا ينبغي أن يتم حقنها في وعاء دموي.</p><p><strong>عند تناول جرعة أكبر من مطلوب</strong><br />إذا كنت تعتقد أنك قد أعطيت الكثير من هذه الحقنة وشعرت بتوعك (انظر القسم 4، الآثار الجانبية المحتملة) ، أخبر طبيب الأسنان<br />الخاص بك.</p><p><strong>إذا نسيت أن تأخذ ميديكاين %2</strong><br />بما أنك ستحصل على هذا الدواء تحت إشراف طبي دقيق ، فمن غير المحتمل أن يتم تفويت جرعة ما. لكن أخبر طبيبك أو الصيدلي<br />إذا كنت تعتقد أن الجرعة قد نسيت.</p><p>إذا كان لديك أي أسئلة أخرى حول استخدام هذا الدواء ، اسأل طبيبك أو الصيدلي أو الممرضة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثل جميع الأدوية، ميديكاين 2% يمكن أن تتسبب في آثار جانبية، على الرغم من عدم حصولها للجميع. أثناء وجودك في عيادة طبيب<br />&nbsp;أسنانك ، سيتبع طبيب أسنانك بعناية آثار ميديكاين %2</p><p>قد يسبب حقن ال ميديكاين 2٪ إرتفاع مستويات المواد الفعالة في الدم )ميبيفاكايين و / أو الأدرينالين) ، خاصة الجرعة الزائدة أو<br />الحقن غير المقصود .تشمل الأعراض: التأثيرات على حواسك (السمع ، البصر ، السلوك) ، التأثيرات على القلب أو الأوعية الدموية ،<br />التأثيرات على دفاعاتك المناعية (تناقص الإحتمال .(كما تشمل المضاعفات على مظاهر نقص الأكسجة الدماغية التدريجي (انخفاض<br />أقل من المستويات الطبيعية للأكسجين في الأنسجة) والتشنجات أو مشكلة القلب والأوعية الدموية ، والتعرق ، والشعور بالضعف ،<br />والتغيرات في النبض أو الحساسية ، قد يحدث تفاعل وعائي مبهمي .يظهر تحفيز الحواس بسبب الأدرينالين عن طريق زيادة الخوف<br />والقلق ، والتوتر ، والأرق ، والخفقان ، والصداع ، والهزة ، والضعف ، والشحوب ، وصعوبة التنفس.<br />&nbsp;</p><p><strong>تؤثر التأثيرات الجانبية الشائعة التالية بين 1 و 10 من كل 100 مريض يتم علاجهم:</strong><br />فشل الدورة الدموية القلبية (الانهيار القلبي الوعائي) والتي قد تؤدي إلى توقف القلب أو خلل في الإيقاع (اضطراب أو خلل ضربات<br />القلب ( ، اضطرابات التوصيل ، انخفاض في ضغط الدم (نقص ضغط الدم) ، التشنجات ، الشعور المبالغ فيه بالسعادة بشكل عام(النشوة) ، فقدان الوعي ، توعك ، ارتباك ، دوخة ، صداع .إذا كنت في وضع رأسي ، قد يتطور رد فعل وعائي مبهمي (يتعلق بعمل<br />العصب على الأوعية الدموية) أو نبضات بطيئة أو سريعة (بطء القلب أو عدم انتظام دقات القلب) ، عدم انتظام القلب (الخفقان) ،<br />الدوخة ، الشعور بالتوتر ) العصبية (، والتخويف ، والإثارة ، والنعاس ، والأزيز في الأذنين (الطنين) ، عدم وضوح الرؤية أو<br />ضعفها ، والغثيان ، والتقيؤ ، وأحاسيس الحرارة والبرد أو خدر ، وحركة العين غير المنضبط (الوخز) ، و الإرتجاف.</p><p><strong>تؤثر التأثيرات الجانبية النادرة التالية بين 1 و 1000 من كل 10،000 مريض تم علاجهم:</strong><br />&bull;شذوذ إيقاع البطين (الرجفان البطيني)</p><p><strong>الآثار الجانبية التالية نادرة جدا تؤثر على 1 من 10000 مريض تم علاجهم:</strong><br />&bull;تفاعلات الحساسية الشديدة (تفاعلات تأقانية) تتميز بتورم في الوجه والشفتين و / أو اللسان ، وصعوبة في التنفس.<br />&bull;ردود الفعل التحسسية التي تتميز بالطفح الجلدي (الآفات الجلدية) ، اندفاع الحكة (الشرى) ، التورم (الوذمة.)<br />إذا أحسست بخطورة الآثار الجانبية المذكورة ، أو إذا لاحظت أي آثار جانبية غير مدرجة في هذه النشرة ، يرجى إخبار طبيب الأسنان<br />الخاص بك.</p><p><strong>الإبلاغ عن الآثار الجانبية</strong><br />إذا كانت أي من الآثار الجانبية خطيرة، أو إذا لاحظت أي آثار جانبية غير مدرجة في هذه النشرة ، يرجى إخبار طبيبك أو مقدم<br />الرعاية الصحية أو الصيدلاني .</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>ابق هذا الدواء بعيدا عن متناول الأطفال.<br />من غير المرجح أن يطلب منك إستعمال هذا الدواء شخصيا.ً<br />لن يستخدم طبيب الأسنان هذا الدواء بعد تاريخ انتهاء الصلاحية المحدد في العبوة. يشير تاريخ انتهاء الصلاحية إلى آخر يوم في ذلك<br />الشهر.<br />سيحافظ طبيب أسنانك على ميديكاين 2% في درجة حرارة تصل إلى 25 درجة مئوية ، مخزنة في الحاوية الأصلية (محمية من<br />الضوء).</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>المادة الفعالة: يحتوي كل مل من محلول الحقن على :<br />20 ملغ من هيدروكلوريد الميبيفاكايين ، -<br />10 ميكروغرام من الأدرينالين -<br />المكونات الأخرى هي: كلوريد الصوديوم ، ميتابيسلفيت الصوديوم والماء للحقن.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>ميديكاين 2٪ هو محلول شفاف، عديم اللون، و بدون جزيئات مرئية معبأ في خرطوشات زجاجية.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>للحصول على أي معلومات حول هذا المنتج الطبي ، يرجى الاتصال بالممثل المحلي لصاحب الترخيص التسويقي:<br />مؤسسة الصالحية للتجارة<br />(المعدات الطبية والمستحضرات الطبية)<br />صندوق البريد: 991 ، الرياض 11421 - المملكة العربية السعودية<br />Tel: 00 966 1 46 46 955</p><p>362 34 46 1 966 fax:00</p><p><img alt="" width="600" height="274" src="data:image/png;base64,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" /></p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            09/2018
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Medicaine 2% ; Solution for Injection.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Mepivacaine 20 mg (for 1 ml). 
Adrenaline bitartrate 0.01819 mg (for 1 ml). 
For the full list of excipients, see section 6.1
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Solution for injection.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Local anesthetic for dental use.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Administration:<br />Infiltration or nerve block injection.</p><p>Adults:<br />Use 1 to a maximum of 3 cartridges.</p><p>Pediatric population:<br />Children from 4 years of age (ca. 20kg body weight) and older (see 4.3)</p><p>Recommended therapeutic dose:</p><p>The quantity to be injected should be determined by the age and weight of the child and the magnitude of the operation.</p><p>The average dosage is 0.75mg/kg=0.025ml of mepivacaine solution per kg body weight.</p><p>Maximum recommended dosage:</p><p>Do not exceed the equivalent of 3mg mepivacaine/kg (0.1ml mepivacaine/kg) of body weight.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Children below 4 years of age (ca. 20 kg body weight),
Hypersensitivity to the active ingredient or to amide type anaesthetics,
Porphyria.
Patient with severe disorders of the atrioventricular conduction not compensated by pace-maker,
Epilepsy not controlled by any treatment,

MEDICAINE 2%, due to the presence of a vasoconstrictor (adrenaline) in the formula, is also contraindicated for patients:
- Suffering from arterial hypertension,
- Suffering from cardiovascular disease,
- If they are under MAOI treatment,
- Under tricyclic antidepressant treatment,
- Presenting any coronary disease,
- Suffering from any valvular affection (usually following infectious rheumatism), which constitutes a special risk.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Warnings </strong></p><p>Dental practitioners who employ local anaesthetic agents should be well versed in diagnosis and management of emergencies which may arise from their use. Resuscitative equipment, oxygen and other resuscitative drugs should be available for immediate use. Do not inject into a blood vessel inject slowly:</p><p>&bull; Tominimise the likelihood of intravascular injection, aspiration should be performed before the local anaesthetic solution is injected. If blood is aspirated, the needle must be repositioned until no return of blood can be elicited by aspiration. Note, however, that the absence of blood in the syringe does not assure that intravascular injection will be avoided and a double aspiration is always recommended.</p><p>Local anaesthetic procedures should be used with caution when there is inflammation and/or sepsis in the region of the proposed injection. Medicaine 2% containing a vasoconstrictor should not be injected repeatedly at the same site because reduced blood flow and increased oxygen consumption in the affected tissues may cause tissue anoxia, delay healing, oedema or necrosis at the injection site.</p><p>Use of the cartridges:<br />Use on one patient during one session of treatment only. If only part is used, the remainder must be discarded.</p><p><strong>Precautions for use</strong></p><p>The safety and effectiveness of mepivacaine depend on proper dosage, correct technique, adequate precautions and readiness for emergencies. Resuscitative equipment, oxygen and other resuscitative drugs should be available for immediate use.</p><p>The lowest dosage that results in effective anaesthesia should be used to avoid high plasma levels and serious adverse effects. Repeated doses of mepivacaine may cause significant increases in blood levels with each repeat dose due to slow accumulation of the drug or its metabolites. Tolerance to elevated blood levels varies with the status of the patient. Debilitated, elderly patients, acutely ill patients, and children should be given reduced doses commensurate with their age and physical condition. (See Posology and Method of Administration):</p><p>&bull; Patients with peripheral vascular disease may exhibit exaggerated vasoconstrictor response.<br />&bull; Cardiovascular and respiratory (adequacy of ventilation) vital signs and the patient&rsquo;s state of consciousness should be monitored after each local anaesthetic injection.<br />&bull; Restlessness, anxiety, tinnitus, dizziness, blurred vision, tremors, depression or drowsiness should alert the practitioner to the possibility of central nervous system toxicity.<br />&bull; Signs and symptoms of depressed cardiovascular function may commonly result from a vasovagal reaction, particularly if the patient is in an upright position.</p><p><em>Mepivacaine should be used with caution in:</em></p><p>&bull; Patients with hepatic disease, since amide-type local anaesthetics are metabolised by the liver. Patients with severe hepatic disease, because of their inability to metabolise local anaesthetics normally, are at greater risk of developing toxic plasma concentration,</p><p>&bull; Patients with renal disease, since local anaesthetics are excreted by the kidneys, and the patient due to his condition is also at a greater risk of developing toxic plasma concentrations. The use of mepivacaine should be carefully considered if:</p><p>&nbsp;- there is inflammation and/or sepsis in the region of injection, since this may alter the pH at the site of injection, resulting in decrease or loss of anaesthetic effect,<br />- there is a history of severe disturbances of cardiac rhythm or heart block, since the cardiac depressant effects of the anaesthetic are detrimental to the patient.<br />- Medicaine 2% should be administered with caution to subjects with epilepsy and impaired respiratory function.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Interaction with other medicaments<br />&bull; As in the case of all other anaesthetic solutions containing adrenaline, the administration of Medicaine 2% in patients receiving phenothiazines may produce severe prolonged hypotension or hypertension. Concurrent use of these agents should generally be avoided. In situations when concurrent therapy is necessary, careful patient monitoring is essential.<br />&bull; Concurrent administration of vasopressor drugs and ergot-type oxytoxic drugs may cause severe, persistent hypertension or cerebrovascular accidents.<br />&bull; If sedatives are employed to reduce patient apprehension, reduced doses of anaesthetic solution should be used since local anaesthetic agents, like sedatives, are central nervous system depressants which in combination may have an additive effect.<br />&bull; Concurrent use of beta-adrenergic blocking agents with an anaesthetic solution containing a vasoconstrictor may result in dose-dependent hypertension and bradycardia.<br />&bull; Serious cardiac arrhythmias may occur if preparations containing a vasoconstrictor are employed in patients during or following the administration of chloroform, halothane, cyclopropane, trichloroethylene or other related agents.<br />&bull; Monoamine oxydase inhibitors (MAOI) and tricyclic antidepressants may increase the cardiovascular effects of adrenaline (produce severe prolonged hypertension).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u><strong>Pregnancy</strong></u></p><p>Pregnancy Category C. Animal reproduction studies have not been conducted with this solution. On the basis of long usage, anaesthetics of the mepivacaine type are considered to be reasonably safe for use onpregnant women.</p><p>Retrospective studies of pregnant women receiving local anaesthetics for emergency surgery early in pregnancy havenot shown that local anaesthetics cause birth defects. However, no controlled studies have been carried out in pregnant women. Moreover, no reproduction studies have been performed with the product. Therefore, caution should be taken before administering this anaesthetic during early pregnancy.</p><p><u><strong>Breast-feeding</strong></u></p><p>It is not known whether local anaesthetics are excreted in human milk. Because many drugs are excreted in humanmilk, caution should be exercised when mepivacaine is administered to a nursing woman</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Mepivacaine hydrochloride may have a minor influence on the ability to drive and use machines. Dizziness (includingvertigo, vision disorder and fatigue) may occur following administration of mepivacaine hydrochloride (see section4.8).</p><p>Patients experiencing these symptoms should not drive or use machinery until any such symptoms havecompletely resolved.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Adverse experiences following the administration of mepivacaine are similar in nature to those observed with other amide local anaesthetic agents. These adverse experiences are, in general, dose-related and may result from high plasma levels caused by excessive dosage, rapid absorption or unintended intra-vascular injection, or may result from a hypersensitivity, idiosyncrasy or diminished tolerance on the part of the patient. Serious adverse experiences are generally systemic in nature. The following types are those most commonly reported:</p><p><u><strong>Central Nervous System </strong></u></p><p>CNS manifestations are excitatory and/or depressant and may be characterised by lightheadedness, nervousness, apprehension, euphoria, confusion, dizziness, drowsiness, tinnitus, blurred or double vision, vomiting, sensations of heat, cold or numbness, twitching, tremors, convulsions, unconsciousness, respiratory depression and arrest The excitatory manifestations may be very brief or may not occur at all, in which case the first manifestation of toxicity may be drowsiness merging into unconsciousness and respiratory arrest Drowsiness following the administration of mepivacaine is usually an early sign of a high blood level of the drug and may occur as a consequence of rapid absorption.</p><p><u><strong>Cardiovascular system</strong></u><br />Cardiovascular manifestations are usually depressant and are characterised by bradycardia, hypotension and cardiovascular collapse, which may lead to cardiac arrest. Signs and symptoms of depressed cardiovascular function may commonly result from a vasovagal reaction, particularly if the patient is in an upright position. Less commonly, they may result from a direct effect of the drug. Failure to recognise the premonitory signs such as sweating, a feeling of faintness, changes in pulse or sensorium may result in progressive cerebral hypoxia and seizure or serious cardiovascular catastrophe. Management consists of placing the patient in the recumbent position and ventilation with oxygen. Supportive treatment of circulatory depression may require the administration of intravenous fluids, and when appropriate, a vasopressor as directed by the clinical situation.</p><p><u><strong>Allergic reactions</strong></u></p><p>Allergic reactions are characterised by cutaneous lesions, urticaria, oedema or anaphylactoid reactions. Allergic reactions as a result of sensitivity to mepivacaine are extremely rare and, if they occur, should be managed by conventional means. The detection of sensitivity by skin testing is of doubtful value.</p><p><u><strong>Due to adrenaline</strong></u></p><p>The clinical manifestations relate to CNS stimulation and include increasing fear and anxiety, tension, restlessness, throbbing headache, tremor, weakness, dizziness, pallor, respiratory difficult, and palpitation. With increasing levels of adrenaline in the blood, cardiac dysrhythmias become more common; ventricular fibrillation is a rare but possible consequence. Dramatic increases in both systolic and diastolic pressures may be noted which have led to cerebral haemorrhage. Anginal episodes may be precipitated in patients with coronary insufficiency. Because of the rapid inactivation of adrenaline, the stimulatory phase of the overdose reaction is usually very brief.</p><p><strong>Reporting of suspected adverse reactions:</strong></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via Saudi vigilance system.</p><p>The National Pharmacovigilance and Drug Safety Centre (NPC)</p><ul><li>Fax: +966-11-205-7662</li><li>Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.</li><li>Toll free phone: 8002490000</li><li>E-mail: npc.drug@sfda.gov.sa</li><li>Website: www.sfda.gov.sa/npc</li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Acute emergencies from local anaesthetics are generally related to high plasma levels encountered during therapeutic use of excessive dosage of local anaesthetics, or to unintended intravascular injection of local anaesthetic solution. (See adverse effects, special warnings and precautions for use).</p><p><strong><u>Management of local anaesthetic emergencies:</u></strong></p><p>The first consideration is prevention, best accomplished by careful and constant monitoring of cardiovascular and respiratory vital signs and the patient&rsquo;s state of consciousness after each local anaesthetic injection. At the first sign of change, oxygen should be administered. The first step in the management of convulsions consists of immediate attention to the maintenance of a patent airway and assisted or controlled ventilation with oxygen and a delivery system capable of permitting immediate positive airway pressure by mask.</p><p>Immediately after institution of these ventilatory measures, the adequacy of the circulation should be evaluated, keeping in mind that drugs used to treat convulsions sometimes depress the circulation when administered intravenously. Should convulsions persist despite adequate respiratory support, and if the status of the circulation permits, small increments of an ultra-short acting barbiturate (such as thiopental or thiamylal) or a benzodiazepine (such as diazepam) may be administered intravenously. The clinician should be familiar, prior to use of local anaesthetics, with these anticonvulsant drugs. Supportive treatment of circulation depression may require administration of intravenous fluids and, when appropriate, a vasopressor as directed by the clinical situation (e.g., ephedrine).</p><p>If not treated immediately, both convulsions and cardiovascular depression can result in hypoxia, acidosis, bradycardia, arrhythmias and cardiac arrest. If cardiac arrest should occur, standard cardiopulmonary resuscitative measures should be instituted. Endotracheal intubation, employing drugs and techniques familiar to the clinician, may be indicated, after initial administration of oxygen by mask, if difficulty is encountered in the maintenance of a patent airway or if prolonged ventilatory support (assisted or controlled) is indicated.</p><p>Dialysis is of negligible value in the treatment of acute overdosage with mepivacaine.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Local anaesthetics for dental use.</p><p>ATC Code: N01BB53.</p><p><em>Mechanism of action: </em></p><p>Mepivacainestabilises the neuronal membrane and prevents the initiation and transmission of nerve impulses, thereby effecting local anaesthesia.<br />Mepivacaine has a slight intrinsic vasoconstrictive action permitting its use alone for an anaesthesia of a relatively short duration.<br />In the Medicaine 2% solution, adrenaline is included with the anaesthetic in order to achieve a deeper and more prolonged anaesthesia:<br />&bull; By localising the solution at the site of the injection, this vasoconstrictor intensifies and prolongs the anaesthetic effect and decreases the rate at which the anaesthetic drug enters the systemic circulation.<br />&bull; The presence of a vasoconstrictor also decreases surgical haemorrhage in the immediate area of injection.<br /><em>Onset and duration of anaesthesia:</em><br />The onset of action is rapid, 30 to 120 seconds in the upper jaw: 1 to 4 minutes in the lower jaw. Medicaine 2% will ordinarily provide an operating anaesthesia of 1 to 2 hours in the upper jaw and 2 to 4 hours in the lower jaw.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Information derived from diverse formulations, concentrations and usages reveals that systemic absorption of mepivacaine is complete following parenteral administration, its rate of absorption depending upon various factors, such as the site of injection and the presence or absence of a vasoconstrictor agent.</p><p>Mepivacaine, because of its amide structure, is not detoxified by the circulating plasma esterases. Mepivacaine is rapidly metabolised. The liver is the principal site of metabolism, with over 50 per cent of the administered dose being excreted into the bile as metabolites. Most of the metabolisedmepivacaine is probably absorbed in the intestine and then excreted into the urine, since only a small percentage is found in the faeces. The principal route of excretion is via the kidneys. Most of the anaesthetic and its metabolites are eliminated within 30 hours. A percentage of up to 16 per cent of the dose administered is excreted unchanged in the urine. It has been shown that hydroxylation and N-demethylation, which are detoxification reactions, play important roles in the metabolism of the anaesthetic. These metabolites of mepivacaine have been identified from adult humans: two phenols, which are excreted almost exclusively as their glucuronide conjugates, and the N demethylated compound (2&rsquo;,6&rsquo;- pipecoloxylidide).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The DL<sub>50</sub> is 39.9 mg/kg in the mouse and 27.8 mg/kg in the rat in the case of intravenous injection. The toxic dose (TD<sub>50</sub>) is 7.2 mg/kg in the dog in case of intravenous administration. The mepivacaine toxic threshold in the man ranges between 5 and 10 &mu;g/ml. The relative toxicity is 0.81, compared to lidocaine and 1, compared to procaine.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Sodium Chloride</p><p>Sodium metabisulfite</p><p>Water for Injections</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the absence of compatibility studies, Medicaine 2% must not be mixed with any other medicinal products.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months. 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;Do not store above 25&deg;C.</p><p>In order to protect from light, keep the cartridge in the outer carton tightly closed.</p><p>Do not freeze.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Cartridges of 1.8 ml.</p><p>Box containing 50 cartridges.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>One cartridge should be used on one patient during one session of treatment only. If only part is used, the remainder must be discarded.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                LES LABORATOIRES MEDIS- S.A. 
Route de Tunis - KM 7 - BP 206 - 8000 Nabeul - Tunisie 
Tel: (216) 72 23 50 06 
Fax: (216) 72 23 51 06 
E-mail: contact@labomedis.com
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                09/2018
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>